Loading…

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

Aberrant β -catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of β -catenin/Wnt pathway activation with clinical outcome and the mecha...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2011-02, Vol.24 (2), p.209-231
Main Authors: Geyer, Felipe C, Lacroix-Triki, Magali, Savage, Kay, Arnedos, Monica, Lambros, Maryou B, MacKay, Alan, Natrajan, Rachael, Reis-Filho, Jorge S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03
cites cdi_FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03
container_end_page 231
container_issue 2
container_start_page 209
container_title Modern pathology
container_volume 24
creator Geyer, Felipe C
Lacroix-Triki, Magali
Savage, Kay
Arnedos, Monica
Lambros, Maryou B
MacKay, Alan
Natrajan, Rachael
Reis-Filho, Jorge S
description Aberrant β -catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of β -catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of β -catenin expression in invasive breast cancers, the correlations between β -catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant β -catenin expression is driven by CTNNB1 ( β -catenin encoding gene) activating mutations. Immunohistochemistry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated patients, using two anti- β -catenin monoclonal antibodies. Selected samples were subjected to CTNNB1 exon 3 mutation analysis by direct gene sequencing. A good correlation between the two β -catenin antibodies was observed (Spearman's r >0.62, P
doi_str_mv 10.1038/modpathol.2010.205
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_849429675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>849429675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03</originalsourceid><addsrcrecordid>eNp9kEtOwzAURS0EgvLZAAPkGaOAf4mTIVT8JAQTGEeu89IaJXawHaDbYiGsCZcWhkxs6_ncI72L0DElZ5Tw8rx3zaDiwnVnjKQZI_kWmtCck4ywMt9GE1JWPONVzvbQfggvhFCRl2wX7TFKZCEKOkEfX5_ZVEWwxuKV7F0tsdLRvKlonMVpOvOgQsRaWQ0em4BVCE6blGnwu4kLHL0ZOsgszFPmDfCwAOvicgA8GyNOzzU2fXp4uKS4H-OP-hDttKoLcLS5D9Dz9dXT9Da7f7y5m17cZ5pXJGaFLoQUhHKuGFeyamQ5g0KCEozxsm2k0JRrIVsJFaVtDhUvqeYtNJQToQg_QKdr7-Dd6wgh1r0JGrpOWXBjqEtRCVYVMk8kW5PauxA8tPXgTa_8sqakXhVe_xVerwpPxyp0stGPsx6av8hvwwngayCkLzsHX7-40du08n_ab7-nkgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>849429675</pqid></control><display><type>article</type><title>β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation</title><source>Nature</source><creator>Geyer, Felipe C ; Lacroix-Triki, Magali ; Savage, Kay ; Arnedos, Monica ; Lambros, Maryou B ; MacKay, Alan ; Natrajan, Rachael ; Reis-Filho, Jorge S</creator><creatorcontrib>Geyer, Felipe C ; Lacroix-Triki, Magali ; Savage, Kay ; Arnedos, Monica ; Lambros, Maryou B ; MacKay, Alan ; Natrajan, Rachael ; Reis-Filho, Jorge S</creatorcontrib><description>Aberrant β -catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of β -catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of β -catenin expression in invasive breast cancers, the correlations between β -catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant β -catenin expression is driven by CTNNB1 ( β -catenin encoding gene) activating mutations. Immunohistochemistry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated patients, using two anti- β -catenin monoclonal antibodies. Selected samples were subjected to CTNNB1 exon 3 mutation analysis by direct gene sequencing. A good correlation between the two β -catenin antibodies was observed (Spearman's r &gt;0.62, P &lt;0.001). Respectively, 31 and 11% of the cases displayed lack/reduction of β -catenin membranous expression and nuclear accumulation. Complete lack of β -catenin expression was significantly associated with invasive lobular carcinoma histological type. Subgroup analysis of non-lobular cancers or non-lobular grade 3 carcinomas revealed that lack/reduction of β -catenin membranous expression and/or nuclear accumulation were significantly associated with oestrogen receptor negativity, absence of HER2 gene amplification and overexpression, lack/reduction of E-cadherin expression and tumours of triple-negative and basal-like phenotype. Univariate survival analysis revealed a significant association between β -catenin nuclear expression and shorter metastasis-free and overall survival in the whole cohort; however, β -catenin nuclear expression was not an independent predictor of outcome in multivariate analysis. No CTNNB1 mutations were identified in the 28 selected breast carcinomas analysed. In conclusion, β -catenin/Wnt pathway activation is preferentially found in triple-negative/basal-like breast carcinomas, is associated with poor clinical outcome and is unlikely to be driven by CTNNB1 mutations in breast cancer.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/modpathol.2010.205</identifier><identifier>PMID: 21076461</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/208/737 ; 631/80/86 ; 692/699/67/1347 ; beta Catenin - genetics ; beta Catenin - metabolism ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Breast Neoplasms - genetics ; Breast Neoplasms - metabolism ; Carcinoma - genetics ; Carcinoma - metabolism ; DNA Mutational Analysis ; Female ; Humans ; Immunohistochemistry ; Laboratory Medicine ; Medicine ; Medicine &amp; Public Health ; Mutation ; original-article ; Pathology ; Phenotype ; Signal Transduction - physiology ; Survival Analysis ; Tissue Array Analysis</subject><ispartof>Modern pathology, 2011-02, Vol.24 (2), p.209-231</ispartof><rights>United States and Canadian Academy of Pathology, Inc. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03</citedby><cites>FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21076461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Geyer, Felipe C</creatorcontrib><creatorcontrib>Lacroix-Triki, Magali</creatorcontrib><creatorcontrib>Savage, Kay</creatorcontrib><creatorcontrib>Arnedos, Monica</creatorcontrib><creatorcontrib>Lambros, Maryou B</creatorcontrib><creatorcontrib>MacKay, Alan</creatorcontrib><creatorcontrib>Natrajan, Rachael</creatorcontrib><creatorcontrib>Reis-Filho, Jorge S</creatorcontrib><title>β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Aberrant β -catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of β -catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of β -catenin expression in invasive breast cancers, the correlations between β -catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant β -catenin expression is driven by CTNNB1 ( β -catenin encoding gene) activating mutations. Immunohistochemistry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated patients, using two anti- β -catenin monoclonal antibodies. Selected samples were subjected to CTNNB1 exon 3 mutation analysis by direct gene sequencing. A good correlation between the two β -catenin antibodies was observed (Spearman's r &gt;0.62, P &lt;0.001). Respectively, 31 and 11% of the cases displayed lack/reduction of β -catenin membranous expression and nuclear accumulation. Complete lack of β -catenin expression was significantly associated with invasive lobular carcinoma histological type. Subgroup analysis of non-lobular cancers or non-lobular grade 3 carcinomas revealed that lack/reduction of β -catenin membranous expression and/or nuclear accumulation were significantly associated with oestrogen receptor negativity, absence of HER2 gene amplification and overexpression, lack/reduction of E-cadherin expression and tumours of triple-negative and basal-like phenotype. Univariate survival analysis revealed a significant association between β -catenin nuclear expression and shorter metastasis-free and overall survival in the whole cohort; however, β -catenin nuclear expression was not an independent predictor of outcome in multivariate analysis. No CTNNB1 mutations were identified in the 28 selected breast carcinomas analysed. In conclusion, β -catenin/Wnt pathway activation is preferentially found in triple-negative/basal-like breast carcinomas, is associated with poor clinical outcome and is unlikely to be driven by CTNNB1 mutations in breast cancer.</description><subject>631/208/737</subject><subject>631/80/86</subject><subject>692/699/67/1347</subject><subject>beta Catenin - genetics</subject><subject>beta Catenin - metabolism</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - metabolism</subject><subject>Carcinoma - genetics</subject><subject>Carcinoma - metabolism</subject><subject>DNA Mutational Analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mutation</subject><subject>original-article</subject><subject>Pathology</subject><subject>Phenotype</subject><subject>Signal Transduction - physiology</subject><subject>Survival Analysis</subject><subject>Tissue Array Analysis</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp9kEtOwzAURS0EgvLZAAPkGaOAf4mTIVT8JAQTGEeu89IaJXawHaDbYiGsCZcWhkxs6_ncI72L0DElZ5Tw8rx3zaDiwnVnjKQZI_kWmtCck4ywMt9GE1JWPONVzvbQfggvhFCRl2wX7TFKZCEKOkEfX5_ZVEWwxuKV7F0tsdLRvKlonMVpOvOgQsRaWQ0em4BVCE6blGnwu4kLHL0ZOsgszFPmDfCwAOvicgA8GyNOzzU2fXp4uKS4H-OP-hDttKoLcLS5D9Dz9dXT9Da7f7y5m17cZ5pXJGaFLoQUhHKuGFeyamQ5g0KCEozxsm2k0JRrIVsJFaVtDhUvqeYtNJQToQg_QKdr7-Dd6wgh1r0JGrpOWXBjqEtRCVYVMk8kW5PauxA8tPXgTa_8sqakXhVe_xVerwpPxyp0stGPsx6av8hvwwngayCkLzsHX7-40du08n_ab7-nkgQ</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Geyer, Felipe C</creator><creator>Lacroix-Triki, Magali</creator><creator>Savage, Kay</creator><creator>Arnedos, Monica</creator><creator>Lambros, Maryou B</creator><creator>MacKay, Alan</creator><creator>Natrajan, Rachael</creator><creator>Reis-Filho, Jorge S</creator><general>Nature Publishing Group US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation</title><author>Geyer, Felipe C ; Lacroix-Triki, Magali ; Savage, Kay ; Arnedos, Monica ; Lambros, Maryou B ; MacKay, Alan ; Natrajan, Rachael ; Reis-Filho, Jorge S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/208/737</topic><topic>631/80/86</topic><topic>692/699/67/1347</topic><topic>beta Catenin - genetics</topic><topic>beta Catenin - metabolism</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - metabolism</topic><topic>Carcinoma - genetics</topic><topic>Carcinoma - metabolism</topic><topic>DNA Mutational Analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mutation</topic><topic>original-article</topic><topic>Pathology</topic><topic>Phenotype</topic><topic>Signal Transduction - physiology</topic><topic>Survival Analysis</topic><topic>Tissue Array Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Geyer, Felipe C</creatorcontrib><creatorcontrib>Lacroix-Triki, Magali</creatorcontrib><creatorcontrib>Savage, Kay</creatorcontrib><creatorcontrib>Arnedos, Monica</creatorcontrib><creatorcontrib>Lambros, Maryou B</creatorcontrib><creatorcontrib>MacKay, Alan</creatorcontrib><creatorcontrib>Natrajan, Rachael</creatorcontrib><creatorcontrib>Reis-Filho, Jorge S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Geyer, Felipe C</au><au>Lacroix-Triki, Magali</au><au>Savage, Kay</au><au>Arnedos, Monica</au><au>Lambros, Maryou B</au><au>MacKay, Alan</au><au>Natrajan, Rachael</au><au>Reis-Filho, Jorge S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>24</volume><issue>2</issue><spage>209</spage><epage>231</epage><pages>209-231</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>Aberrant β -catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of β -catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of β -catenin expression in invasive breast cancers, the correlations between β -catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant β -catenin expression is driven by CTNNB1 ( β -catenin encoding gene) activating mutations. Immunohistochemistry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated patients, using two anti- β -catenin monoclonal antibodies. Selected samples were subjected to CTNNB1 exon 3 mutation analysis by direct gene sequencing. A good correlation between the two β -catenin antibodies was observed (Spearman's r &gt;0.62, P &lt;0.001). Respectively, 31 and 11% of the cases displayed lack/reduction of β -catenin membranous expression and nuclear accumulation. Complete lack of β -catenin expression was significantly associated with invasive lobular carcinoma histological type. Subgroup analysis of non-lobular cancers or non-lobular grade 3 carcinomas revealed that lack/reduction of β -catenin membranous expression and/or nuclear accumulation were significantly associated with oestrogen receptor negativity, absence of HER2 gene amplification and overexpression, lack/reduction of E-cadherin expression and tumours of triple-negative and basal-like phenotype. Univariate survival analysis revealed a significant association between β -catenin nuclear expression and shorter metastasis-free and overall survival in the whole cohort; however, β -catenin nuclear expression was not an independent predictor of outcome in multivariate analysis. No CTNNB1 mutations were identified in the 28 selected breast carcinomas analysed. In conclusion, β -catenin/Wnt pathway activation is preferentially found in triple-negative/basal-like breast carcinomas, is associated with poor clinical outcome and is unlikely to be driven by CTNNB1 mutations in breast cancer.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>21076461</pmid><doi>10.1038/modpathol.2010.205</doi><tpages>23</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0893-3952
ispartof Modern pathology, 2011-02, Vol.24 (2), p.209-231
issn 0893-3952
1530-0285
language eng
recordid cdi_proquest_miscellaneous_849429675
source Nature
subjects 631/208/737
631/80/86
692/699/67/1347
beta Catenin - genetics
beta Catenin - metabolism
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Carcinoma - genetics
Carcinoma - metabolism
DNA Mutational Analysis
Female
Humans
Immunohistochemistry
Laboratory Medicine
Medicine
Medicine & Public Health
Mutation
original-article
Pathology
Phenotype
Signal Transduction - physiology
Survival Analysis
Tissue Array Analysis
title β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T01%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B2-Catenin%20pathway%20activation%20in%20breast%20cancer%20is%20associated%20with%20triple-negative%20phenotype%20but%20not%20with%20CTNNB1%20mutation&rft.jtitle=Modern%20pathology&rft.au=Geyer,%20Felipe%20C&rft.date=2011-02-01&rft.volume=24&rft.issue=2&rft.spage=209&rft.epage=231&rft.pages=209-231&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1038/modpathol.2010.205&rft_dat=%3Cproquest_cross%3E849429675%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-6c64740133a23a79d78be67ea42238fd74c13c47f7e911f5e9381c3fed1304a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=849429675&rft_id=info:pmid/21076461&rfr_iscdi=true